1190217-35-6
1190217-35-6 結(jié)構(gòu)式
基本信息
ASP7663 >=98% (HPLC)
ASP 7663
ASP-7663
ASP7663
(2E)-2-[7-Fluoro-1,2-dihydro-1-(2-methylpropyl)-2-oxo-3H-indol-3-ylidene]acetic acid
Acetic acid, 2-[7-fluoro-1,2-dihydro-1-(2-methylpropyl)-2-oxo-3H-indol-3-ylidene]-, (2E)-
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/02/08 | HY-101907 | ASP7663 | 1190217-35-6 | 1 mg | 419元 |
| 2025/02/08 | HY-101907 | ASP 7663;ASP-7663;ASP7663 ASP7663 | 1190217-35-6 | 5mg | 1000元 |
| 2025/02/08 | HY-101907 | ASP 7663;ASP-7663;ASP7663 ASP7663 | 1190217-35-6 | 10mM * 1mLin DMSO | 1213元 |
常見問題列表
ASP7663 concentration dependently increases intracellular Ca
2+
concentration in human, rat, and mouse TRPA1 expressed in HEK293 cells in a similar manner, with respective EC
50
values (95% confidence interval [CI]) of 0.51 (0.40–0.66), 0.54 (0.41–0.72), and 0.50 (0.41–0.63) μmol/L.
ASP7663 concentration-dependently stimulates 5-HT release from QGP-1 cells, a lineage of TRPA1-expressing EC cells, with an EC50 value of 72.5 (52.6–99.9) μmol/L.
ASP7663 significantly improves the loperamide-induced delay in colonic transit in mice.
ASP7663 (orally, 0.3 and 1 mg/kg) significantly shortens the prolonged bead expulsion time caused by loperamide.
ASP7663 (orally, 1 and 3 mg/kg) exhibits inhibitory effects on colorectal distension in rat.
| Animal Model: | CRD model (colorectal distension in rat). |
| Dosage: | 1 and 3 mg/kg. |
| Administration: | Orally. |
| Result: | Significantly reduced the number of abdominal contractions evoked during CRD at pressures of 30, 45, and 60 mmHg. ASP7663 also reduced the number of abdominal contractions by intravenous treatment. |